Global Erectile Dysfunction Drugs Market

Erectile Dysfunction Drugs Comprehensive Study by Type (Existing Drugs, Pipeline Drugs), Distribution Channel (Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce), Pipeline Drugs (Apomorphine (Uprima), Alprostadil (Vitaros), Topiglan, Gene Therapy, Melanocortin Activators), Existing Drugs (Sildenafil Citrate (Viagra), Vardenafil (Levitra/Staxyn), Tadalafil (Cialis), Udenafil (Zydena), Lodenafil Carbonate (Helleva), Stendra/Spedra (Avanafil), Mirodenafil (Mvix)), Mode of Medication (Oral Medications, Topical Medications, Injections, Others) Players and Region - Global Market Outlook to 2030

Erectile Dysfunction Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Erectile Dysfunction Drugs
The adoption of unhealthier lifestyles, rising geriatric population, as well as the prevalence of chronic diseases, has increased the instances of sexual problems worldwide. Thus, with the increasing adoption about the availability and safety of the Erectile Dysfunction has significantly increased the demand for the same. Erectile Dysfunction (ED) which is also known as impotence is a type of disease which is characterized as the incapability to build or sustain or maintain a penile erection while sexual intercourse. However, many such drugs have various side effects that might hamper the demand for the ED Drugs but with upsurging research and developments in ED, drug development will stabilize and furthermore increase the demand for ED drugs.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
CAGR6.5%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.The Players having a strong hold in the market are Apricus Biosciences Inc., Bayer AG, Dong-A Pharmaceutical Co. Ltd., Meda Pharmaceuticals, Inc.. Analyst at AMA Research estimates that American Players will contribute the maximum growth to Global Erectile Dysfunction Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Apricus Biosciences Inc. (United States), Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil), Bayer AG (Germany), Dong-A Pharmaceutical Co. Ltd. (South Korea), Meda Pharmaceuticals, Inc. (United States), Eli Lilly and Company (United States), Pfizer, Inc. (United States) and S.K. Chemicals Co. Ltd. (South Korea) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Vivus, Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Erectile Dysfunction Drugs market by Type (Existing Drugs and Pipeline Drugs) and Region.



On the basis of geography, the market of Erectile Dysfunction Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Erectile Dysfunction Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Pipeline Drugs, the sub-segment i.e. Apomorphine (Uprima) will boost the Erectile Dysfunction Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Existing Drugs, the sub-segment i.e. Sildenafil Citrate (Viagra) will boost the Erectile Dysfunction Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Mode of Medication, the sub-segment i.e. Oral Medications will boost the Erectile Dysfunction Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Adoption of Erectile Dysfunction Drugs with Minimal Side Effects and Introduction to New Drug Types Including Uprima, Topiglan, Melanocortin Activators, Gene Therapy, and Many Others

Market Growth Drivers:
Rising Instances of Chronic Diseases and Increasing Obesity among the global Population and Increasing Adoption of Unhealthier Lifestyles Leading to Increased Instances

Challenges:
Stringent Regulations and Manufacturing Standards in the Pharmaceutical Industry and Minimizing the Side Effects of the Existing Drugs and Increasing Global Availability

Restraints:
Several Side Effects and Risks of the Erectile Dysfunction Drug Consumption and Patent Expiration in Pharmaceutical Industry Minimizes Profitability

Opportunities:
Growing Awareness about the Erectile Dysfunction Drugs and their availability worldwide and Robust Research and Developments for Enhancing Erectile Dysfunction Drugs and Minimizing Side Effects

Market Leaders and their expansionary development strategies
In February 2024, Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of two brands, Cialis (Tadalafil) and Alimta (Pemetrexed), from Eli Lilly and Company (“Lilly”) for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte. Ltd. (“Zanovex”).
In January 2024, Akums Drugs and Pharmaceuticals, launched an advancement in healthcare the Tamsulosin + Tadalafil Capsule. The new launch drug for enlarged prostate & erectile dysfunction treatment.
The Canadian Food and Drugs Act prohibits the use of promotional activities and direct-to-consumer advertising (DTCA) of prescription drugs due to growing concerns about patients' misunderstanding of a drug's benefits/risks, thereby contributing to potential misuse, specifically increased demand by patients (Findlay 2001) and pressure on physicians (Lurie 2009) to prescribe marketed drugs.

Key Target Audience
Erectile Dysfunction Drug Manufacturers, Erectile Dysfunction Drug Distributors and Traders, Upstream and Downstream Buyers, Pharmaceutical Industry Associations, Government Regulators, Hospitals & Clinics, Research and Development Firms and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Existing Drugs
  • Pipeline Drugs
By Distribution Channel
  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce

By Pipeline Drugs
  • Apomorphine (Uprima)
  • Alprostadil (Vitaros)
  • Topiglan
  • Gene Therapy
  • Melanocortin Activators

By Existing Drugs
  • Sildenafil Citrate (Viagra)
  • Vardenafil (Levitra/Staxyn)
  • Tadalafil (Cialis)
  • Udenafil (Zydena)
  • Lodenafil Carbonate (Helleva)
  • Stendra/Spedra (Avanafil)
  • Mirodenafil (Mvix)

By Mode of Medication
  • Oral Medications
  • Topical Medications
  • Injections
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Instances of Chronic Diseases and Increasing Obesity among the global Population
      • 3.2.2. Increasing Adoption of Unhealthier Lifestyles Leading to Increased Instances
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulations and Manufacturing Standards in the Pharmaceutical Industry
      • 3.3.2. Minimizing the Side Effects of the Existing Drugs and Increasing Global Availability
    • 3.4. Market Trends
      • 3.4.1. Adoption of Erectile Dysfunction Drugs with Minimal Side Effects
      • 3.4.2. Introduction to New Drug Types Including Uprima, Topiglan, Melanocortin Activators, Gene Therapy, and Many Others
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Erectile Dysfunction Drugs, by Type, Distribution Channel, Pipeline Drugs, Existing Drugs, Mode of Medication and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Erectile Dysfunction Drugs (Value)
      • 5.2.1. Global Erectile Dysfunction Drugs by: Type (Value)
        • 5.2.1.1. Existing Drugs
        • 5.2.1.2. Pipeline Drugs
      • 5.2.2. Global Erectile Dysfunction Drugs by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Private Clinics
        • 5.2.2.3. Drug Stores
        • 5.2.2.4. Retail Pharmacies
        • 5.2.2.5. E-Commerce
      • 5.2.3. Global Erectile Dysfunction Drugs by: Pipeline Drugs (Value)
        • 5.2.3.1. Apomorphine (Uprima)
        • 5.2.3.2. Alprostadil (Vitaros)
        • 5.2.3.3. Topiglan
        • 5.2.3.4. Gene Therapy
        • 5.2.3.5. Melanocortin Activators
      • 5.2.4. Global Erectile Dysfunction Drugs by: Existing Drugs (Value)
        • 5.2.4.1. Sildenafil Citrate (Viagra)
        • 5.2.4.2. Vardenafil (Levitra/Staxyn)
        • 5.2.4.3. Tadalafil (Cialis)
        • 5.2.4.4. Udenafil (Zydena)
        • 5.2.4.5. Lodenafil Carbonate (Helleva)
        • 5.2.4.6. Stendra/Spedra (Avanafil)
        • 5.2.4.7. Mirodenafil (Mvix)
      • 5.2.5. Global Erectile Dysfunction Drugs by: Mode of Medication (Value)
        • 5.2.5.1. Oral Medications
        • 5.2.5.2. Topical Medications
        • 5.2.5.3. Injections
        • 5.2.5.4. Others
      • 5.2.6. Global Erectile Dysfunction Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Erectile Dysfunction Drugs (Volume)
      • 5.3.1. Global Erectile Dysfunction Drugs by: Type (Volume)
        • 5.3.1.1. Existing Drugs
        • 5.3.1.2. Pipeline Drugs
      • 5.3.2. Global Erectile Dysfunction Drugs by: Distribution Channel (Volume)
        • 5.3.2.1. Hospital Pharmacies
        • 5.3.2.2. Private Clinics
        • 5.3.2.3. Drug Stores
        • 5.3.2.4. Retail Pharmacies
        • 5.3.2.5. E-Commerce
      • 5.3.3. Global Erectile Dysfunction Drugs by: Pipeline Drugs (Volume)
        • 5.3.3.1. Apomorphine (Uprima)
        • 5.3.3.2. Alprostadil (Vitaros)
        • 5.3.3.3. Topiglan
        • 5.3.3.4. Gene Therapy
        • 5.3.3.5. Melanocortin Activators
      • 5.3.4. Global Erectile Dysfunction Drugs by: Existing Drugs (Volume)
        • 5.3.4.1. Sildenafil Citrate (Viagra)
        • 5.3.4.2. Vardenafil (Levitra/Staxyn)
        • 5.3.4.3. Tadalafil (Cialis)
        • 5.3.4.4. Udenafil (Zydena)
        • 5.3.4.5. Lodenafil Carbonate (Helleva)
        • 5.3.4.6. Stendra/Spedra (Avanafil)
        • 5.3.4.7. Mirodenafil (Mvix)
      • 5.3.5. Global Erectile Dysfunction Drugs by: Mode of Medication (Volume)
        • 5.3.5.1. Oral Medications
        • 5.3.5.2. Topical Medications
        • 5.3.5.3. Injections
        • 5.3.5.4. Others
      • 5.3.6. Global Erectile Dysfunction Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Erectile Dysfunction Drugs (Price)
      • 5.4.1. Global Erectile Dysfunction Drugs by: Type (Price)
  • 6. Erectile Dysfunction Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Apricus Biosciences Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Dong-A Pharmaceutical Co. Ltd. (South Korea)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Meda Pharmaceuticals, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. S.K. Chemicals Co. Ltd. (South Korea)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Erectile Dysfunction Drugs Sale, by Type, Distribution Channel, Pipeline Drugs, Existing Drugs, Mode of Medication and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Erectile Dysfunction Drugs (Value)
      • 7.2.1. Global Erectile Dysfunction Drugs by: Type (Value)
        • 7.2.1.1. Existing Drugs
        • 7.2.1.2. Pipeline Drugs
      • 7.2.2. Global Erectile Dysfunction Drugs by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Private Clinics
        • 7.2.2.3. Drug Stores
        • 7.2.2.4. Retail Pharmacies
        • 7.2.2.5. E-Commerce
      • 7.2.3. Global Erectile Dysfunction Drugs by: Pipeline Drugs (Value)
        • 7.2.3.1. Apomorphine (Uprima)
        • 7.2.3.2. Alprostadil (Vitaros)
        • 7.2.3.3. Topiglan
        • 7.2.3.4. Gene Therapy
        • 7.2.3.5. Melanocortin Activators
      • 7.2.4. Global Erectile Dysfunction Drugs by: Existing Drugs (Value)
        • 7.2.4.1. Sildenafil Citrate (Viagra)
        • 7.2.4.2. Vardenafil (Levitra/Staxyn)
        • 7.2.4.3. Tadalafil (Cialis)
        • 7.2.4.4. Udenafil (Zydena)
        • 7.2.4.5. Lodenafil Carbonate (Helleva)
        • 7.2.4.6. Stendra/Spedra (Avanafil)
        • 7.2.4.7. Mirodenafil (Mvix)
      • 7.2.5. Global Erectile Dysfunction Drugs by: Mode of Medication (Value)
        • 7.2.5.1. Oral Medications
        • 7.2.5.2. Topical Medications
        • 7.2.5.3. Injections
        • 7.2.5.4. Others
      • 7.2.6. Global Erectile Dysfunction Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Erectile Dysfunction Drugs (Volume)
      • 7.3.1. Global Erectile Dysfunction Drugs by: Type (Volume)
        • 7.3.1.1. Existing Drugs
        • 7.3.1.2. Pipeline Drugs
      • 7.3.2. Global Erectile Dysfunction Drugs by: Distribution Channel (Volume)
        • 7.3.2.1. Hospital Pharmacies
        • 7.3.2.2. Private Clinics
        • 7.3.2.3. Drug Stores
        • 7.3.2.4. Retail Pharmacies
        • 7.3.2.5. E-Commerce
      • 7.3.3. Global Erectile Dysfunction Drugs by: Pipeline Drugs (Volume)
        • 7.3.3.1. Apomorphine (Uprima)
        • 7.3.3.2. Alprostadil (Vitaros)
        • 7.3.3.3. Topiglan
        • 7.3.3.4. Gene Therapy
        • 7.3.3.5. Melanocortin Activators
      • 7.3.4. Global Erectile Dysfunction Drugs by: Existing Drugs (Volume)
        • 7.3.4.1. Sildenafil Citrate (Viagra)
        • 7.3.4.2. Vardenafil (Levitra/Staxyn)
        • 7.3.4.3. Tadalafil (Cialis)
        • 7.3.4.4. Udenafil (Zydena)
        • 7.3.4.5. Lodenafil Carbonate (Helleva)
        • 7.3.4.6. Stendra/Spedra (Avanafil)
        • 7.3.4.7. Mirodenafil (Mvix)
      • 7.3.5. Global Erectile Dysfunction Drugs by: Mode of Medication (Volume)
        • 7.3.5.1. Oral Medications
        • 7.3.5.2. Topical Medications
        • 7.3.5.3. Injections
        • 7.3.5.4. Others
      • 7.3.6. Global Erectile Dysfunction Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Erectile Dysfunction Drugs (Price)
      • 7.4.1. Global Erectile Dysfunction Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Erectile Dysfunction Drugs: by Type(USD Million)
  • Table 2. Erectile Dysfunction Drugs Existing Drugs , by Region USD Million (2018-2023)
  • Table 3. Erectile Dysfunction Drugs Pipeline Drugs , by Region USD Million (2018-2023)
  • Table 4. Erectile Dysfunction Drugs: by Distribution Channel(USD Million)
  • Table 5. Erectile Dysfunction Drugs Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 6. Erectile Dysfunction Drugs Private Clinics , by Region USD Million (2018-2023)
  • Table 7. Erectile Dysfunction Drugs Drug Stores , by Region USD Million (2018-2023)
  • Table 8. Erectile Dysfunction Drugs Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 9. Erectile Dysfunction Drugs E-Commerce , by Region USD Million (2018-2023)
  • Table 10. Erectile Dysfunction Drugs: by Pipeline Drugs(USD Million)
  • Table 11. Erectile Dysfunction Drugs Apomorphine (Uprima) , by Region USD Million (2018-2023)
  • Table 12. Erectile Dysfunction Drugs Alprostadil (Vitaros) , by Region USD Million (2018-2023)
  • Table 13. Erectile Dysfunction Drugs Topiglan , by Region USD Million (2018-2023)
  • Table 14. Erectile Dysfunction Drugs Gene Therapy , by Region USD Million (2018-2023)
  • Table 15. Erectile Dysfunction Drugs Melanocortin Activators , by Region USD Million (2018-2023)
  • Table 16. Erectile Dysfunction Drugs: by Existing Drugs(USD Million)
  • Table 17. Erectile Dysfunction Drugs Sildenafil Citrate (Viagra) , by Region USD Million (2018-2023)
  • Table 18. Erectile Dysfunction Drugs Vardenafil (Levitra/Staxyn) , by Region USD Million (2018-2023)
  • Table 19. Erectile Dysfunction Drugs Tadalafil (Cialis) , by Region USD Million (2018-2023)
  • Table 20. Erectile Dysfunction Drugs Udenafil (Zydena) , by Region USD Million (2018-2023)
  • Table 21. Erectile Dysfunction Drugs Lodenafil Carbonate (Helleva) , by Region USD Million (2018-2023)
  • Table 22. Erectile Dysfunction Drugs Stendra/Spedra (Avanafil) , by Region USD Million (2018-2023)
  • Table 23. Erectile Dysfunction Drugs Mirodenafil (Mvix) , by Region USD Million (2018-2023)
  • Table 24. Erectile Dysfunction Drugs: by Mode of Medication(USD Million)
  • Table 25. Erectile Dysfunction Drugs Oral Medications , by Region USD Million (2018-2023)
  • Table 26. Erectile Dysfunction Drugs Topical Medications , by Region USD Million (2018-2023)
  • Table 27. Erectile Dysfunction Drugs Injections , by Region USD Million (2018-2023)
  • Table 28. Erectile Dysfunction Drugs Others , by Region USD Million (2018-2023)
  • Table 29. South America Erectile Dysfunction Drugs, by Country USD Million (2018-2023)
  • Table 30. South America Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 31. South America Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 32. South America Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 33. South America Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 34. South America Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 35. Brazil Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 36. Brazil Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 37. Brazil Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 38. Brazil Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 39. Brazil Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 40. Argentina Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 41. Argentina Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 42. Argentina Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 43. Argentina Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 44. Argentina Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 45. Rest of South America Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 46. Rest of South America Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 47. Rest of South America Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 48. Rest of South America Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 49. Rest of South America Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 50. Asia Pacific Erectile Dysfunction Drugs, by Country USD Million (2018-2023)
  • Table 51. Asia Pacific Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 52. Asia Pacific Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 53. Asia Pacific Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 54. Asia Pacific Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 55. Asia Pacific Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 56. China Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 57. China Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 58. China Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 59. China Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 60. China Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 61. Japan Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 62. Japan Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 63. Japan Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 64. Japan Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 65. Japan Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 66. India Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 67. India Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 68. India Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 69. India Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 70. India Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 71. South Korea Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 72. South Korea Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 73. South Korea Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 74. South Korea Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 75. South Korea Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 76. Taiwan Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 77. Taiwan Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 78. Taiwan Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 79. Taiwan Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 80. Taiwan Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 81. Australia Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 82. Australia Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 83. Australia Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 84. Australia Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 85. Australia Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 89. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 90. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 91. Europe Erectile Dysfunction Drugs, by Country USD Million (2018-2023)
  • Table 92. Europe Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 93. Europe Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 94. Europe Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 95. Europe Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 96. Europe Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 97. Germany Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 98. Germany Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 99. Germany Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 100. Germany Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 101. Germany Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 102. France Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 103. France Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 104. France Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 105. France Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 106. France Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 107. Italy Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 108. Italy Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 109. Italy Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 110. Italy Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 111. Italy Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 112. United Kingdom Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 113. United Kingdom Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 114. United Kingdom Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 115. United Kingdom Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 116. United Kingdom Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 117. Netherlands Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 118. Netherlands Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 119. Netherlands Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 120. Netherlands Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 121. Netherlands Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 122. Rest of Europe Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 123. Rest of Europe Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 124. Rest of Europe Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 125. Rest of Europe Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 126. Rest of Europe Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 127. MEA Erectile Dysfunction Drugs, by Country USD Million (2018-2023)
  • Table 128. MEA Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 129. MEA Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 130. MEA Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 131. MEA Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 132. MEA Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 133. Middle East Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 134. Middle East Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 135. Middle East Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 136. Middle East Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 137. Middle East Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 138. Africa Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 139. Africa Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 140. Africa Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 141. Africa Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 142. Africa Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 143. North America Erectile Dysfunction Drugs, by Country USD Million (2018-2023)
  • Table 144. North America Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 145. North America Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 146. North America Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 147. North America Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 148. North America Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 149. United States Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 150. United States Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 151. United States Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 152. United States Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 153. United States Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 154. Canada Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 155. Canada Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 156. Canada Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 157. Canada Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 158. Canada Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 159. Mexico Erectile Dysfunction Drugs, by Type USD Million (2018-2023)
  • Table 160. Mexico Erectile Dysfunction Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 161. Mexico Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2018-2023)
  • Table 162. Mexico Erectile Dysfunction Drugs, by Existing Drugs USD Million (2018-2023)
  • Table 163. Mexico Erectile Dysfunction Drugs, by Mode of Medication USD Million (2018-2023)
  • Table 164. Erectile Dysfunction Drugs Sales: by Type(Tons)
  • Table 165. Erectile Dysfunction Drugs Sales Existing Drugs , by Region Tons (2018-2023)
  • Table 166. Erectile Dysfunction Drugs Sales Pipeline Drugs , by Region Tons (2018-2023)
  • Table 167. Erectile Dysfunction Drugs Sales: by Distribution Channel(Tons)
  • Table 168. Erectile Dysfunction Drugs Sales Hospital Pharmacies , by Region Tons (2018-2023)
  • Table 169. Erectile Dysfunction Drugs Sales Private Clinics , by Region Tons (2018-2023)
  • Table 170. Erectile Dysfunction Drugs Sales Drug Stores , by Region Tons (2018-2023)
  • Table 171. Erectile Dysfunction Drugs Sales Retail Pharmacies , by Region Tons (2018-2023)
  • Table 172. Erectile Dysfunction Drugs Sales E-Commerce , by Region Tons (2018-2023)
  • Table 173. Erectile Dysfunction Drugs Sales: by Pipeline Drugs(Tons)
  • Table 174. Erectile Dysfunction Drugs Sales Apomorphine (Uprima) , by Region Tons (2018-2023)
  • Table 175. Erectile Dysfunction Drugs Sales Alprostadil (Vitaros) , by Region Tons (2018-2023)
  • Table 176. Erectile Dysfunction Drugs Sales Topiglan , by Region Tons (2018-2023)
  • Table 177. Erectile Dysfunction Drugs Sales Gene Therapy , by Region Tons (2018-2023)
  • Table 178. Erectile Dysfunction Drugs Sales Melanocortin Activators , by Region Tons (2018-2023)
  • Table 179. Erectile Dysfunction Drugs Sales: by Existing Drugs(Tons)
  • Table 180. Erectile Dysfunction Drugs Sales Sildenafil Citrate (Viagra) , by Region Tons (2018-2023)
  • Table 181. Erectile Dysfunction Drugs Sales Vardenafil (Levitra/Staxyn) , by Region Tons (2018-2023)
  • Table 182. Erectile Dysfunction Drugs Sales Tadalafil (Cialis) , by Region Tons (2018-2023)
  • Table 183. Erectile Dysfunction Drugs Sales Udenafil (Zydena) , by Region Tons (2018-2023)
  • Table 184. Erectile Dysfunction Drugs Sales Lodenafil Carbonate (Helleva) , by Region Tons (2018-2023)
  • Table 185. Erectile Dysfunction Drugs Sales Stendra/Spedra (Avanafil) , by Region Tons (2018-2023)
  • Table 186. Erectile Dysfunction Drugs Sales Mirodenafil (Mvix) , by Region Tons (2018-2023)
  • Table 187. Erectile Dysfunction Drugs Sales: by Mode of Medication(Tons)
  • Table 188. Erectile Dysfunction Drugs Sales Oral Medications , by Region Tons (2018-2023)
  • Table 189. Erectile Dysfunction Drugs Sales Topical Medications , by Region Tons (2018-2023)
  • Table 190. Erectile Dysfunction Drugs Sales Injections , by Region Tons (2018-2023)
  • Table 191. Erectile Dysfunction Drugs Sales Others , by Region Tons (2018-2023)
  • Table 192. South America Erectile Dysfunction Drugs Sales, by Country Tons (2018-2023)
  • Table 193. South America Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 194. South America Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 195. South America Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 196. South America Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 197. South America Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 198. Brazil Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 199. Brazil Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 200. Brazil Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 201. Brazil Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 202. Brazil Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 203. Argentina Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 204. Argentina Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 205. Argentina Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 206. Argentina Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 207. Argentina Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 208. Rest of South America Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 209. Rest of South America Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 210. Rest of South America Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 211. Rest of South America Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 212. Rest of South America Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 213. Asia Pacific Erectile Dysfunction Drugs Sales, by Country Tons (2018-2023)
  • Table 214. Asia Pacific Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 215. Asia Pacific Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 216. Asia Pacific Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 217. Asia Pacific Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 218. Asia Pacific Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 219. China Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 220. China Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 221. China Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 222. China Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 223. China Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 224. Japan Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 225. Japan Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 226. Japan Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 227. Japan Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 228. Japan Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 229. India Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 230. India Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 231. India Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 232. India Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 233. India Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 234. South Korea Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 235. South Korea Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 236. South Korea Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 237. South Korea Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 238. South Korea Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 239. Taiwan Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 240. Taiwan Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 241. Taiwan Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 242. Taiwan Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 243. Taiwan Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 244. Australia Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 245. Australia Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 246. Australia Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 247. Australia Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 248. Australia Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 249. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 250. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 251. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 252. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 253. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 254. Europe Erectile Dysfunction Drugs Sales, by Country Tons (2018-2023)
  • Table 255. Europe Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 256. Europe Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 257. Europe Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 258. Europe Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 259. Europe Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 260. Germany Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 261. Germany Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 262. Germany Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 263. Germany Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 264. Germany Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 265. France Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 266. France Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 267. France Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 268. France Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 269. France Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 270. Italy Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 271. Italy Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 272. Italy Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 273. Italy Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 274. Italy Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 275. United Kingdom Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 276. United Kingdom Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 277. United Kingdom Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 278. United Kingdom Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 279. United Kingdom Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 280. Netherlands Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 281. Netherlands Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 282. Netherlands Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 283. Netherlands Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 284. Netherlands Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 285. Rest of Europe Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 286. Rest of Europe Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 287. Rest of Europe Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 288. Rest of Europe Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 289. Rest of Europe Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 290. MEA Erectile Dysfunction Drugs Sales, by Country Tons (2018-2023)
  • Table 291. MEA Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 292. MEA Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 293. MEA Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 294. MEA Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 295. MEA Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 296. Middle East Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 297. Middle East Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 298. Middle East Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 299. Middle East Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 300. Middle East Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 301. Africa Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 302. Africa Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 303. Africa Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 304. Africa Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 305. Africa Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 306. North America Erectile Dysfunction Drugs Sales, by Country Tons (2018-2023)
  • Table 307. North America Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 308. North America Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 309. North America Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 310. North America Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 311. North America Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 312. United States Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 313. United States Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 314. United States Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 315. United States Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 316. United States Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 317. Canada Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 318. Canada Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 319. Canada Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 320. Canada Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 321. Canada Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 322. Mexico Erectile Dysfunction Drugs Sales, by Type Tons (2018-2023)
  • Table 323. Mexico Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2018-2023)
  • Table 324. Mexico Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2018-2023)
  • Table 325. Mexico Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2018-2023)
  • Table 326. Mexico Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2018-2023)
  • Table 327. Erectile Dysfunction Drugs: by Type(USD/Units)
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Company Basic Information, Sales Area and Its Competitors
  • Table 335. Company Basic Information, Sales Area and Its Competitors
  • Table 336. Erectile Dysfunction Drugs: by Type(USD Million)
  • Table 337. Erectile Dysfunction Drugs Existing Drugs , by Region USD Million (2025-2030)
  • Table 338. Erectile Dysfunction Drugs Pipeline Drugs , by Region USD Million (2025-2030)
  • Table 339. Erectile Dysfunction Drugs: by Distribution Channel(USD Million)
  • Table 340. Erectile Dysfunction Drugs Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 341. Erectile Dysfunction Drugs Private Clinics , by Region USD Million (2025-2030)
  • Table 342. Erectile Dysfunction Drugs Drug Stores , by Region USD Million (2025-2030)
  • Table 343. Erectile Dysfunction Drugs Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 344. Erectile Dysfunction Drugs E-Commerce , by Region USD Million (2025-2030)
  • Table 345. Erectile Dysfunction Drugs: by Pipeline Drugs(USD Million)
  • Table 346. Erectile Dysfunction Drugs Apomorphine (Uprima) , by Region USD Million (2025-2030)
  • Table 347. Erectile Dysfunction Drugs Alprostadil (Vitaros) , by Region USD Million (2025-2030)
  • Table 348. Erectile Dysfunction Drugs Topiglan , by Region USD Million (2025-2030)
  • Table 349. Erectile Dysfunction Drugs Gene Therapy , by Region USD Million (2025-2030)
  • Table 350. Erectile Dysfunction Drugs Melanocortin Activators , by Region USD Million (2025-2030)
  • Table 351. Erectile Dysfunction Drugs: by Existing Drugs(USD Million)
  • Table 352. Erectile Dysfunction Drugs Sildenafil Citrate (Viagra) , by Region USD Million (2025-2030)
  • Table 353. Erectile Dysfunction Drugs Vardenafil (Levitra/Staxyn) , by Region USD Million (2025-2030)
  • Table 354. Erectile Dysfunction Drugs Tadalafil (Cialis) , by Region USD Million (2025-2030)
  • Table 355. Erectile Dysfunction Drugs Udenafil (Zydena) , by Region USD Million (2025-2030)
  • Table 356. Erectile Dysfunction Drugs Lodenafil Carbonate (Helleva) , by Region USD Million (2025-2030)
  • Table 357. Erectile Dysfunction Drugs Stendra/Spedra (Avanafil) , by Region USD Million (2025-2030)
  • Table 358. Erectile Dysfunction Drugs Mirodenafil (Mvix) , by Region USD Million (2025-2030)
  • Table 359. Erectile Dysfunction Drugs: by Mode of Medication(USD Million)
  • Table 360. Erectile Dysfunction Drugs Oral Medications , by Region USD Million (2025-2030)
  • Table 361. Erectile Dysfunction Drugs Topical Medications , by Region USD Million (2025-2030)
  • Table 362. Erectile Dysfunction Drugs Injections , by Region USD Million (2025-2030)
  • Table 363. Erectile Dysfunction Drugs Others , by Region USD Million (2025-2030)
  • Table 364. South America Erectile Dysfunction Drugs, by Country USD Million (2025-2030)
  • Table 365. South America Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 366. South America Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 367. South America Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 368. South America Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 369. South America Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 370. Brazil Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 371. Brazil Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 372. Brazil Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 373. Brazil Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 374. Brazil Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 375. Argentina Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 376. Argentina Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 377. Argentina Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 378. Argentina Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 379. Argentina Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 380. Rest of South America Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 381. Rest of South America Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 382. Rest of South America Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 383. Rest of South America Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 384. Rest of South America Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 385. Asia Pacific Erectile Dysfunction Drugs, by Country USD Million (2025-2030)
  • Table 386. Asia Pacific Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 387. Asia Pacific Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 388. Asia Pacific Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 389. Asia Pacific Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 390. Asia Pacific Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 391. China Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 392. China Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 393. China Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 394. China Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 395. China Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 396. Japan Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 397. Japan Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 398. Japan Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 399. Japan Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 400. Japan Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 401. India Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 402. India Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 403. India Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 404. India Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 405. India Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 406. South Korea Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 407. South Korea Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 408. South Korea Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 409. South Korea Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 410. South Korea Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 411. Taiwan Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 412. Taiwan Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 413. Taiwan Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 414. Taiwan Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 415. Taiwan Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 416. Australia Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 417. Australia Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 418. Australia Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 419. Australia Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 420. Australia Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 421. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 422. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 423. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 424. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 425. Rest of Asia-Pacific Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 426. Europe Erectile Dysfunction Drugs, by Country USD Million (2025-2030)
  • Table 427. Europe Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 428. Europe Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 429. Europe Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 430. Europe Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 431. Europe Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 432. Germany Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 433. Germany Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 434. Germany Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 435. Germany Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 436. Germany Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 437. France Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 438. France Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 439. France Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 440. France Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 441. France Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 442. Italy Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 443. Italy Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 444. Italy Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 445. Italy Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 446. Italy Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 447. United Kingdom Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 448. United Kingdom Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 449. United Kingdom Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 450. United Kingdom Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 451. United Kingdom Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 452. Netherlands Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 453. Netherlands Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 454. Netherlands Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 455. Netherlands Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 456. Netherlands Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 457. Rest of Europe Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 458. Rest of Europe Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 459. Rest of Europe Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 460. Rest of Europe Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 461. Rest of Europe Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 462. MEA Erectile Dysfunction Drugs, by Country USD Million (2025-2030)
  • Table 463. MEA Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 464. MEA Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 465. MEA Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 466. MEA Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 467. MEA Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 468. Middle East Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 469. Middle East Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 470. Middle East Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 471. Middle East Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 472. Middle East Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 473. Africa Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 474. Africa Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 475. Africa Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 476. Africa Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 477. Africa Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 478. North America Erectile Dysfunction Drugs, by Country USD Million (2025-2030)
  • Table 479. North America Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 480. North America Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 481. North America Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 482. North America Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 483. North America Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 484. United States Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 485. United States Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 486. United States Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 487. United States Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 488. United States Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 489. Canada Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 490. Canada Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 491. Canada Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 492. Canada Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 493. Canada Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 494. Mexico Erectile Dysfunction Drugs, by Type USD Million (2025-2030)
  • Table 495. Mexico Erectile Dysfunction Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 496. Mexico Erectile Dysfunction Drugs, by Pipeline Drugs USD Million (2025-2030)
  • Table 497. Mexico Erectile Dysfunction Drugs, by Existing Drugs USD Million (2025-2030)
  • Table 498. Mexico Erectile Dysfunction Drugs, by Mode of Medication USD Million (2025-2030)
  • Table 499. Erectile Dysfunction Drugs Sales: by Type(Tons)
  • Table 500. Erectile Dysfunction Drugs Sales Existing Drugs , by Region Tons (2025-2030)
  • Table 501. Erectile Dysfunction Drugs Sales Pipeline Drugs , by Region Tons (2025-2030)
  • Table 502. Erectile Dysfunction Drugs Sales: by Distribution Channel(Tons)
  • Table 503. Erectile Dysfunction Drugs Sales Hospital Pharmacies , by Region Tons (2025-2030)
  • Table 504. Erectile Dysfunction Drugs Sales Private Clinics , by Region Tons (2025-2030)
  • Table 505. Erectile Dysfunction Drugs Sales Drug Stores , by Region Tons (2025-2030)
  • Table 506. Erectile Dysfunction Drugs Sales Retail Pharmacies , by Region Tons (2025-2030)
  • Table 507. Erectile Dysfunction Drugs Sales E-Commerce , by Region Tons (2025-2030)
  • Table 508. Erectile Dysfunction Drugs Sales: by Pipeline Drugs(Tons)
  • Table 509. Erectile Dysfunction Drugs Sales Apomorphine (Uprima) , by Region Tons (2025-2030)
  • Table 510. Erectile Dysfunction Drugs Sales Alprostadil (Vitaros) , by Region Tons (2025-2030)
  • Table 511. Erectile Dysfunction Drugs Sales Topiglan , by Region Tons (2025-2030)
  • Table 512. Erectile Dysfunction Drugs Sales Gene Therapy , by Region Tons (2025-2030)
  • Table 513. Erectile Dysfunction Drugs Sales Melanocortin Activators , by Region Tons (2025-2030)
  • Table 514. Erectile Dysfunction Drugs Sales: by Existing Drugs(Tons)
  • Table 515. Erectile Dysfunction Drugs Sales Sildenafil Citrate (Viagra) , by Region Tons (2025-2030)
  • Table 516. Erectile Dysfunction Drugs Sales Vardenafil (Levitra/Staxyn) , by Region Tons (2025-2030)
  • Table 517. Erectile Dysfunction Drugs Sales Tadalafil (Cialis) , by Region Tons (2025-2030)
  • Table 518. Erectile Dysfunction Drugs Sales Udenafil (Zydena) , by Region Tons (2025-2030)
  • Table 519. Erectile Dysfunction Drugs Sales Lodenafil Carbonate (Helleva) , by Region Tons (2025-2030)
  • Table 520. Erectile Dysfunction Drugs Sales Stendra/Spedra (Avanafil) , by Region Tons (2025-2030)
  • Table 521. Erectile Dysfunction Drugs Sales Mirodenafil (Mvix) , by Region Tons (2025-2030)
  • Table 522. Erectile Dysfunction Drugs Sales: by Mode of Medication(Tons)
  • Table 523. Erectile Dysfunction Drugs Sales Oral Medications , by Region Tons (2025-2030)
  • Table 524. Erectile Dysfunction Drugs Sales Topical Medications , by Region Tons (2025-2030)
  • Table 525. Erectile Dysfunction Drugs Sales Injections , by Region Tons (2025-2030)
  • Table 526. Erectile Dysfunction Drugs Sales Others , by Region Tons (2025-2030)
  • Table 527. South America Erectile Dysfunction Drugs Sales, by Country Tons (2025-2030)
  • Table 528. South America Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 529. South America Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 530. South America Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 531. South America Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 532. South America Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 533. Brazil Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 534. Brazil Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 535. Brazil Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 536. Brazil Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 537. Brazil Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 538. Argentina Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 539. Argentina Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 540. Argentina Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 541. Argentina Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 542. Argentina Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 543. Rest of South America Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 544. Rest of South America Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 545. Rest of South America Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 546. Rest of South America Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 547. Rest of South America Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 548. Asia Pacific Erectile Dysfunction Drugs Sales, by Country Tons (2025-2030)
  • Table 549. Asia Pacific Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 550. Asia Pacific Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 551. Asia Pacific Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 552. Asia Pacific Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 553. Asia Pacific Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 554. China Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 555. China Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 556. China Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 557. China Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 558. China Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 559. Japan Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 560. Japan Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 561. Japan Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 562. Japan Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 563. Japan Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 564. India Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 565. India Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 566. India Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 567. India Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 568. India Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 569. South Korea Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 570. South Korea Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 571. South Korea Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 572. South Korea Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 573. South Korea Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 574. Taiwan Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 575. Taiwan Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 576. Taiwan Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 577. Taiwan Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 578. Taiwan Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 579. Australia Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 580. Australia Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 581. Australia Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 582. Australia Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 583. Australia Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 584. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 585. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 586. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 587. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 588. Rest of Asia-Pacific Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 589. Europe Erectile Dysfunction Drugs Sales, by Country Tons (2025-2030)
  • Table 590. Europe Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 591. Europe Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 592. Europe Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 593. Europe Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 594. Europe Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 595. Germany Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 596. Germany Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 597. Germany Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 598. Germany Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 599. Germany Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 600. France Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 601. France Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 602. France Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 603. France Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 604. France Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 605. Italy Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 606. Italy Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 607. Italy Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 608. Italy Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 609. Italy Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 610. United Kingdom Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 611. United Kingdom Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 612. United Kingdom Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 613. United Kingdom Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 614. United Kingdom Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 615. Netherlands Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 616. Netherlands Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 617. Netherlands Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 618. Netherlands Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 619. Netherlands Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 620. Rest of Europe Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 621. Rest of Europe Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 622. Rest of Europe Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 623. Rest of Europe Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 624. Rest of Europe Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 625. MEA Erectile Dysfunction Drugs Sales, by Country Tons (2025-2030)
  • Table 626. MEA Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 627. MEA Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 628. MEA Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 629. MEA Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 630. MEA Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 631. Middle East Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 632. Middle East Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 633. Middle East Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 634. Middle East Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 635. Middle East Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 636. Africa Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 637. Africa Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 638. Africa Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 639. Africa Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 640. Africa Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 641. North America Erectile Dysfunction Drugs Sales, by Country Tons (2025-2030)
  • Table 642. North America Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 643. North America Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 644. North America Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 645. North America Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 646. North America Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 647. United States Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 648. United States Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 649. United States Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 650. United States Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 651. United States Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 652. Canada Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 653. Canada Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 654. Canada Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 655. Canada Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 656. Canada Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 657. Mexico Erectile Dysfunction Drugs Sales, by Type Tons (2025-2030)
  • Table 658. Mexico Erectile Dysfunction Drugs Sales, by Distribution Channel Tons (2025-2030)
  • Table 659. Mexico Erectile Dysfunction Drugs Sales, by Pipeline Drugs Tons (2025-2030)
  • Table 660. Mexico Erectile Dysfunction Drugs Sales, by Existing Drugs Tons (2025-2030)
  • Table 661. Mexico Erectile Dysfunction Drugs Sales, by Mode of Medication Tons (2025-2030)
  • Table 662. Erectile Dysfunction Drugs: by Type(USD/Units)
  • Table 663. Research Programs/Design for This Report
  • Table 664. Key Data Information from Secondary Sources
  • Table 665. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Erectile Dysfunction Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Erectile Dysfunction Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Erectile Dysfunction Drugs: by Pipeline Drugs USD Million (2018-2023)
  • Figure 7. Global Erectile Dysfunction Drugs: by Existing Drugs USD Million (2018-2023)
  • Figure 8. Global Erectile Dysfunction Drugs: by Mode of Medication USD Million (2018-2023)
  • Figure 9. South America Erectile Dysfunction Drugs Share (%), by Country
  • Figure 10. Asia Pacific Erectile Dysfunction Drugs Share (%), by Country
  • Figure 11. Europe Erectile Dysfunction Drugs Share (%), by Country
  • Figure 12. MEA Erectile Dysfunction Drugs Share (%), by Country
  • Figure 13. North America Erectile Dysfunction Drugs Share (%), by Country
  • Figure 14. Global Erectile Dysfunction Drugs: by Type Tons (2018-2023)
  • Figure 15. Global Erectile Dysfunction Drugs: by Distribution Channel Tons (2018-2023)
  • Figure 16. Global Erectile Dysfunction Drugs: by Pipeline Drugs Tons (2018-2023)
  • Figure 17. Global Erectile Dysfunction Drugs: by Existing Drugs Tons (2018-2023)
  • Figure 18. Global Erectile Dysfunction Drugs: by Mode of Medication Tons (2018-2023)
  • Figure 19. South America Erectile Dysfunction Drugs Share (%), by Country
  • Figure 20. Asia Pacific Erectile Dysfunction Drugs Share (%), by Country
  • Figure 21. Europe Erectile Dysfunction Drugs Share (%), by Country
  • Figure 22. MEA Erectile Dysfunction Drugs Share (%), by Country
  • Figure 23. North America Erectile Dysfunction Drugs Share (%), by Country
  • Figure 24. Global Erectile Dysfunction Drugs: by Type USD/Units (2018-2023)
  • Figure 25. Global Erectile Dysfunction Drugs share by Players 2023 (%)
  • Figure 26. Global Erectile Dysfunction Drugs share by Players (Top 3) 2023(%)
  • Figure 27. Global Erectile Dysfunction Drugs share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Apricus Biosciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Apricus Biosciences Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil) Revenue, Net Income and Gross profit
  • Figure 32. Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil) Revenue: by Geography 2023
  • Figure 33. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 35. Dong-A Pharmaceutical Co. Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 36. Dong-A Pharmaceutical Co. Ltd. (South Korea) Revenue: by Geography 2023
  • Figure 37. Meda Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Meda Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 40. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 41. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 43. S.K. Chemicals Co. Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 44. S.K. Chemicals Co. Ltd. (South Korea) Revenue: by Geography 2023
  • Figure 45. Global Erectile Dysfunction Drugs: by Type USD Million (2025-2030)
  • Figure 46. Global Erectile Dysfunction Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 47. Global Erectile Dysfunction Drugs: by Pipeline Drugs USD Million (2025-2030)
  • Figure 48. Global Erectile Dysfunction Drugs: by Existing Drugs USD Million (2025-2030)
  • Figure 49. Global Erectile Dysfunction Drugs: by Mode of Medication USD Million (2025-2030)
  • Figure 50. South America Erectile Dysfunction Drugs Share (%), by Country
  • Figure 51. Asia Pacific Erectile Dysfunction Drugs Share (%), by Country
  • Figure 52. Europe Erectile Dysfunction Drugs Share (%), by Country
  • Figure 53. MEA Erectile Dysfunction Drugs Share (%), by Country
  • Figure 54. North America Erectile Dysfunction Drugs Share (%), by Country
  • Figure 55. Global Erectile Dysfunction Drugs: by Type Tons (2025-2030)
  • Figure 56. Global Erectile Dysfunction Drugs: by Distribution Channel Tons (2025-2030)
  • Figure 57. Global Erectile Dysfunction Drugs: by Pipeline Drugs Tons (2025-2030)
  • Figure 58. Global Erectile Dysfunction Drugs: by Existing Drugs Tons (2025-2030)
  • Figure 59. Global Erectile Dysfunction Drugs: by Mode of Medication Tons (2025-2030)
  • Figure 60. South America Erectile Dysfunction Drugs Share (%), by Country
  • Figure 61. Asia Pacific Erectile Dysfunction Drugs Share (%), by Country
  • Figure 62. Europe Erectile Dysfunction Drugs Share (%), by Country
  • Figure 63. MEA Erectile Dysfunction Drugs Share (%), by Country
  • Figure 64. North America Erectile Dysfunction Drugs Share (%), by Country
  • Figure 65. Global Erectile Dysfunction Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Apricus Biosciences Inc. (United States)
  • Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil)
  • Bayer AG (Germany)
  • Dong-A Pharmaceutical Co. Ltd. (South Korea)
  • Meda Pharmaceuticals, Inc. (United States)
  • Eli Lilly and Company (United States)
  • Pfizer, Inc. (United States)
  • S.K. Chemicals Co. Ltd. (South Korea)
Additional players considered in the study are as follows:
Vivus, Inc. (United States) , Teva Pharmaceutical Industries Ltd. (Israel) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 220 Pages 85 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Erectile Dysfunction Drugs Market Quantitative research analysis
Global Erectile Dysfunction Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Apricus Biosciences Inc. (United States), Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil), Bayer AG (Germany), Dong-A Pharmaceutical Co. Ltd. (South Korea), Meda Pharmaceuticals, Inc. (United States), Eli Lilly and Company (United States), Pfizer, Inc. (United States) and S.K. Chemicals Co. Ltd. (South Korea) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Adoption of Erectile Dysfunction Drugs with Minimal Side Effects " is seen as one of major influencing trends for Erectile Dysfunction Drugs Market during projected period 2023-2030.
The Erectile Dysfunction Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Erectile Dysfunction Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Tea Capsules Comprehensive Study by Type (Red Tea Capsules, Oolong Tea Capsules, Black Tea Capsules, Yellow Tea Capsules), Application (Residential, Commercial), Category (Children, Adults), Distribu...
$ 3450
Lyophilized Antivenins Comprehensive Study by Type (Neurotoxin, Blood Toxin, Mixed Toxin), Application (Hospital, Medical Center), Route of Administration (Intravenous Injection, Infusion), Strength ...
$ 3500
Vitamin B9 Comprehensive Study by Application (Food & beverages, Pharmaceuticals, Nutraceuticals, Others), Disease (Alzheimer's, Memory Loss, Weak Bones, Hearing Loss, Sleep Problems, Others), Source...
$ 3750
Capsule Polisher Comprehensive Study by Type (With Metal Detector, With Sorter, Others), Application (Pharmaceutical, Nutraceutical, Others), Capacity (Upto 50,000/hr., 50,000 – 80,000/hr., 80,000 – ...
$ 3450
Sugar-Based Excipients Comprehensive Study by Type (Actual Sugars, Sugar Alcohols, Artificial Sweeteners, Others), Formulations (Oral Formulations, Parenteral Formulations, Topical Formulations, Othe...
$ 3750
Ivermectin Comprehensive Study by Application (Hospitals, Clinics, Research Centre), Form (Oral Tablet, Cream, Lotion), End User (Aged 18-65 Years, Aged 0-17 Years, Aged 65 and Above) Players and Reg...
$ 3500